Dechra Pharmaceuticals (BATS-CHIXE:DPHL) - Aktienkurs, Nachrichten und Analyse

DPHL Aktienübersicht

Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. Mehr Details

DPHL grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	1/6
Künftiges Wachstum	4/6
Vergangene Leistung	0/6
Finanzielle Gesundheit	1/6
Dividenden	0/6

Belohnungen

Prognostiziertes Gewinnwachstum 62.48% pro Jahr

Risikoanalyse

Zinszahlungen sind nicht ausreichend durch Erträge gedeckt

Dechra Pharmaceuticals PLC Wettbewerber

Hikma Pharmaceuticals

LSE:HIK

UK£4.4b

HUTCHMED (China)

AIM:HCM

UK£2.4b

Indivior

LSE:INDV

UK£1.1b

GSK

LSE:GSK

UK£54.6b

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Dechra Pharmaceuticals
Historische Aktienkurse
Aktueller Aktienkurs	UK£38.70
52-Wochen-Hoch	UK£38.84
52-Wochen-Tief	UK£24.74
Beta	0.78
11 Monat Veränderung	0.55%
3 Monate Veränderung	2.27%
1 Jahr Veränderung	35.79%
33 Jahre Veränderung	5.91%
5 Jahre Veränderung	63.71%
Veränderung seit IPO	744.98%

Aktuelle Nachrichten und Updates

Recent updates

Aktionärsrenditen

	DPHL	GB Pharmaceuticals	GB Markt
7D	0.2%	4.2%	1.7%
1Y	35.8%	3.0%	8.4%

Rendite im Vergleich zur Industrie: DPHL übertraf die Branche UK Pharmaceuticals , die im vergangenen Jahr eine Rendite von 3 erzielte.

Rendite vs. Markt: DPHL übertraf den Markt UK, der im vergangenen Jahr eine Rendite von 8.4 erzielte.

Preisvolatilität

Is DPHL's price volatile compared to industry and market?
DPHL volatility
DPHL Average Weekly Movement	0.5%
Pharmaceuticals Industry Average Movement	6.5%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.3%
10% least volatile stocks in GB Market	2.6%

Stabiler Aktienkurs: DPHL hat in den letzten 3 Monaten keine nennenswerten Preisschwankungen aufgewiesen.

Volatilität im Zeitverlauf: DPHLDie wöchentliche Volatilität der Aktie ist im vergangenen Jahr von 6% auf 1% zurückgegangen.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
1997	2,457	Ian Page	www.dechra.com

Dechra Pharmaceuticals PLC's Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Dechra Pharmaceuticals im Vergleich zum Marktanteil des Unternehmens?
DPHL grundlegende Statistiken
Marktanteil	UK£4.40b
Gewinn(TTM)	-UK£27.90m
Umsatz(TTM)	UK£761.50m

5.8x

Kurs-Umsatz-Verhältnis

-157.8x

Kurs-Gewinn-Verhältnis

Ist DPHL zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
DPHL Gewinn- und Verlustrechnung (TTM)
Einnahmen	UK£761.50m
Kosten der Einnahmen	UK£331.90m
Bruttogewinn	UK£429.60m
Sonstige Ausgaben	UK£457.50m
Umsatz	-UK£27.90m

Zuletzt gemeldete Gewinne

Jun 30, 2023

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-0.24
Bruttomarge	56.42%
Nettogewinnspanne	-3.66%
Schulden/Eigenkapital-Verhältnis	64.6%

Wie hat sich DPHL auf lange Sicht entwickelt?

Historische Performance und Vergleiche

DPHL Aktienübersicht

Belohnungen

Risikoanalyse

Dechra Pharmaceuticals PLC Wettbewerber

LSE:HIK

UK£4.4b

AIM:HCM

UK£2.4b

LSE:INDV

UK£1.1b

LSE:GSK

UK£54.6b

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.

Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.

Dechra Pharmaceuticals Limited reached agreement in principle to acquire 33.34% stake in STEM Animal Health Inc. for $4.7 million.

Dechra Group Holdings Limited Announces Resignation of Sara Huda as Director

EQT X EUR SCSp and EQT X USD SCSp managed by Eqt Fund Management S.à R.L. and Luxinva SA (the Offerors) completed the acquisition of Dechra Pharmaceuticals PLC (LSE:DPH).

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE All-Share Index (GBP)

Recent updates

Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.

Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.

Dechra Pharmaceuticals Limited reached agreement in principle to acquire 33.34% stake in STEM Animal Health Inc. for $4.7 million.

Dechra Group Holdings Limited Announces Resignation of Sara Huda as Director

EQT X EUR SCSp and EQT X USD SCSp managed by Eqt Fund Management S.à R.L. and Luxinva SA (the Offerors) completed the acquisition of Dechra Pharmaceuticals PLC (LSE:DPH).

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE All-Share Index (GBP)

Dechra Pharmaceuticals' Cancellation of Listing and Admission to Trading of Shares Expected on 17 January 2024

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals PLC to Report Fiscal Year 2023 Results on Oct 12, 2023

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 250 (Ex Investment Companies) Index (GBP)

Dechra Pharmaceuticals plc Announces Resignation of Ishbel Macpherson as Non-Executive Director

Dechra Pharmaceuticals Intends to Delist from Official List

First half 2023 earnings released: EPS: UK£0.20 (vs UK£0.38 in 1H 2022)

Investor sentiment improved over the past week

Dechra Pharmaceuticals PLC Appoints Geeta Gopalan as A Non-Executive Director of the Company

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 100 Index

Now 21% undervalued after recent price drop

Less than half of directors are independent

Upcoming dividend of UK£0.33 per share

Dechra Pharmaceuticals PLC, Annual General Meeting, Oct 19, 2023

Full year 2022 earnings released: EPS: UK£0.54 (vs UK£0.51 in FY 2021)

Dechra Pharmaceuticals plc Proposes Final Dividend for the Year Ended June 30, 2022

Dechra Pharmaceuticals PLC (LSE:DPH) acquired Med-Pharmex, Inc. from DW Management Services, LLC for $260 million on a debt-free and cash-free basis.

Dechra Pharmaceuticals PLC (LSE : DPH) agreed to acquire Piedmont Animal Health LLC for approximately $210 million.

Now 21% undervalued after recent price drop

Dechra Pharmaceuticals PLC Announces Executive Changes

Less than half of directors are independent

Non-Executive Chairman recently bought UK£99k worth of stock

Upcoming dividend of UK£0.12 per share

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Dechra Pharmaceuticals PLC Declares Interim Dividend, Payable on April 7, 2022

Dechra Pharmaceuticals plc Announces Executive Changes

Dechra Pharmaceuticals PLC (LSE:DPH) agreed to acquire Worldwide Rights to Verdinexor from Anivive Lifesciences, Inc.

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 250 (Ex Investment Companies) Index (GBP)

Non-Executive Director Denise Goode has left the company

Upcoming dividend of UK£0.29 per share

Board Member recently sold UK£875k worth of stock

Full year 2021 earnings released: EPS UK£0.51 (vs UK£0.33 in FY 2020)

Board Member recently sold UK£963k worth of stock

First half 2021 earnings released: EPS UK£0.22 (vs UK£0.13 in 1H 2020)

Akston Biosciences Signs Licensing Agreement with Dechra Pharma for Aks-425C

New 90-day high: UK£37.50

Dechra Pharmaceuticals PLC, Annual General Meeting, Oct 21, 2021

New 90-day high: UK£35.98

Dechra Pharmaceuticals PLC Launches Mirataz

Dechra Pharmaceuticals PLC to Report First Half, 2021 Results on Feb 22, 2021

Aktionärsrenditen

Preisvolatilität

Über das Unternehmen

Dechra Pharmaceuticals PLC's Grundlagenzusammenfassung

5.8x

-157.8x

Erträge &amp; Einnahmen

Erträge & Einnahmen